MedTrace Logo

Imatinib in Acute Ischaemic Stroke

NCT03639922 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1260

Last updated 2020-09-16

No results posted yet for this study

Summary

A clinical trial comparing treatment with Imatinib to placebo when administered within 8 hours of stroke onset for 6 days, in addition to conventional stroke treatment after acute ischaemic stroke.

Conditions

  • Acute Ischaemic Stroke

Interventions

DRUG

Imatinib 400mg

2 tablets of Imatinib 400mg per day for 6 days

DRUG

Placebo Oral Tablet

2 tablets of placebo per day for 6 days

Sponsors & Collaborators

  • Niaz Ahmed

    lead OTHER

Principal Investigators

  • Niaz Ahmed, MD PhD · Karolinska Institutet

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-01
Primary Completion
2022-12-31
Completion
2023-06-30

Countries

  • Sweden

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03639922 on ClinicalTrials.gov